Guggenheim Reiterates Buy on Zenas BioPharma, Maintains $55 Price Target
Benzinga Newsdesk 2 months ago
Analyst RatingsNewsReiterationPrice Target
Guggenheim analyst Yatin Suneja reiterates Zenas BioPharma (NASDAQ:ZBIO) with a Buy and maintains $55 price target.
Guggenheim analyst Yatin Suneja reiterates Zenas BioPharma (NASDAQ:ZBIO) with a Buy and maintains $55 price target.